New drug duo takes on tough head and neck cancers
NCT ID NCT05054439
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a new drug called SI-B001 combined with the chemotherapy paclitaxel in 42 adults with recurrent or metastatic head and neck squamous cell carcinoma. Participants have already tried standard treatments like immunotherapy or platinum chemo. The study aims to see if the combination can shrink tumors and control the disease longer, while monitoring safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SI-B001 (a targeted drug) combined with paclitaxel (a chemotherapy drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced head and neck cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial (42 people) with no control group, so results may not be definitive. Side effects from the drug combination are possible and being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, 200120, China
-
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
-
Union Hospital Tongji Medical College， Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?